Carazolol
In this article, we are going to delve deeper into the topic of Carazolol and explore all its facets. Carazolol is a relevant topic and of great interest to a wide audience, as it affects many areas of our daily lives. Throughout this article, we will examine different aspects related to Carazolol, from its historical origin to its impact on today's society. Through a detailed analysis, we will try to shed light on this issue and provide a more complete view of what it really entails. We hope that upon completion of reading, readers will gain a deeper understanding and appreciation of Carazolol's topic.
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATCvet code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.055.387 |
| Chemical and physical data | |
| Formula | C18H22N2O2 |
| Molar mass | 298.386 g·mol−1 |
| 3D model (JSmol) | |
| |
Carazolol is a high affinity inverse agonist (also referred to as a beta blocker) of the β-adrenergic receptor.[1]
References
- ^ Innis RB, Corrēa FM, Synder SH (1979). "Carazolol, an extremely potent beta-adrenergic blocker: binding to beta-receptors in brain membranes". Life Sci. 24 (24): 2255–64. doi:10.1016/0024-3205(79)90102-4. PMID 41147.
External links
- Carazolol at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |